Safety of Fluralaner Chewable Tablets Bravecto® in Dogs with Dermatitis–Clinical Pathology Parameters Evaluation

Medication selection should always take into account the fact that therapeutic efficiency means obtaining a pharmacologic response with the desired intensity and duration of drug action, while avoiding adverse reactions. In the case of fluralaner, adverse reactions are mild and transitory gastrointestinal symptoms such as diarrhea, vomiting, inappetence, hypersalivation, and neurological manifestation as toxic effects. Assessment of serum biochemical markers is crucial for determining the extent of organ and tissue damage. For this reason, the aim of this paper was to evaluate some clinical pathology parameters as a result of using a controversial product like Bravecto® chewable tablets, with fluralaner as the active ingredient. To fulfill the purpose of the study Bravecto® tablets were administered to a group of dogs with a pre-existing pathology of allergic dermatitis. Serum biochemistry examination was performed after 15-20 days, following possible adverse effects and/or toxic effects and the possible alterations of the assessed clinical pathology parameters. According to our study we can appreciate that during the metabolization of fluralaner, the only statistically relevant (R2=0.79) changes were related to alkaline phosphatase values.